The mechanism of action of the sulfonylureas in diabetes mellitus rachmiel levine, gerald w sobel diabetes may 1957, 6 3 263269. The first of these includes nateglinide, tolbutamide and gliclazide, which are molecules that bind specifically the a site of sur1, while the second group, which includes glimepiri. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext. Sulfonylureas are associated with the highest risk of hypoglycemia. Mechanisms of the glycaemic effects of sulfonylureas. Antidiabetic drugs knowledge for medical students and physicians. Pdf diabetes mellitus dm is one of the most prevalent chronic diseases and has been a leading cause of death in the last decades.
These drugs exert their hypoglycaemic effects by stimulating insulin secretion. In this video i explain the mechanism of action of sulfonylureas witch are a very popular class of treatment for type ii diabetes. The pharmacology, efficacy, indications, and side effects of these drugs will be. Sulfonylureas have been extensively used for treatment of type 2 diabetes for nearly 50 years and, even in our times, are widely used for treatment of this devastating chronic illness. Sulfonylureas and their use in clinical practice ncbi.
Meglitinides glinides are based on the sulfonylurea moiety of glibenclamide called meglitinide. Adverse effects may include weight gain and hypoglycemia. Drugs that potentiate or prolong the effects of sulfonylureas and therefore. Key disposition factors protein binding in sulfonylureas relative onset of action and relationship to mechanism or other factors relative duration of action and factors that influence duration of action metabolic processes and activity of metabolites contribution to therapeutic activity. Sulfonylureas and meglitinides in the treatment of type 2 diabetes. These drugs exert their hypoglycaemic effects by stimulating insulin secretion from the pancreatic betacell. Sulfonylureas are widely used to treat noninsulin dependent diabetes mellitus. The mechanism of action of the sulfonylureas in diabetes. Many antidiabetic drugs with different mechanisms of action are now available for treatment of type 2 diabetes mellitus. Sulfonylureas lower blood glucose levels by stimulating insulin release from the beta cells of the pancreas. Their primary mechanism of action is to close atpsensitive kchannels in the betacell plasma membrane, and so initiate a chain of events which results in insulin release. These drugs may be classified according to their mechanism of action as insulinotropic or. Extrapancreatic effects of sulfonylureas may contribute to glucose control in patients with diabetes mellitus.
1505 414 445 766 1212 415 636 395 1246 1082 1404 715 445 612 387 1328 1177 1036 228 160 1359 499 623 990 1468 750 174 1297 1071 1026 1334 1001 639 233 481 614 1299